Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC. Read more about Reduction of revascularization in patients with hypertriglyceridemia with icosapent ethyl: insights from REDUCE-IT REVASC.
EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial. Read more about EPA levels and cardiovascular outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.
Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial). Read more about Association between triglycerides and residual cardiovascular risk in patients with type 2 diabetes mellitus and established cardiovascular disease (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes [BARI 2D] trial).
A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review. Read more about A Response to: Letter to the Editor Regarding “Critical Differences Between Dietary Supplement and Prescription Omega-3 Fatty Acids: a Narrative Review.
Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice? Read more about Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?
Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections Read more about Amarin Supports Investigator-Initiated Trial at Kaiser Permanente in the U.S. to Study the Effects of VASCEPA® (icosapent ethyl) in Reducing Viral Upper Respiratory Infections, Including COVID-19 and Flu, and the Clinical Severity of Such Infections
Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe Read more about Amarin Announces Plans to Maximize Blockbuster Potential of VASCEPA® (icosapent ethyl) in Europe
Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations Read more about Amarin Reports Second Quarter 2020 Financial Results and Provides Update on Operations
VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention Read more about VASCEPA® (icosapent ethyl) Data from REDUCE-IT® REVASC, Including New Data on Timeframe to Demonstrated Benefit, Presented as Encore at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD (Cardiovascular Disease) Prevention
Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020 Read more about Amarin to Report Second Quarter 2020 Results and Host Conference Call on August 4, 2020